Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Roth Mkm's Rating of Provectus Biopharmaceuticals on 4/12/2012

On April 12, 2012, Roth Mkm updated its outlook on Provectus Biopharmaceuticals (OTCMKTS:PVCT) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Roth Mkm

DateCompanyAction
5/22/2026
Target Corporation stock logo
TGT
Target
Reiterated Rating
5/22/2026
Enersys stock logo
ENS
Enersys
Reiterated Rating
5/22/2026
Enphase Energy, Inc. stock logo
ENPH
Enphase Energy
Reiterated Rating
5/21/2026
Tamboran Resources Corporation stock logo
TBN
Tamboran Resources
Initiated Coverage
5/20/2026
SailPoint, Inc. stock logo
SAIL
SailPoint
Upgrade
5/21/2026
Etsy Inc stock logo
ETSY
Etsy
Initiated Coverage
More Ratings From Roth Mkm